fluoxetine has been researched along with Chronic Progressive Multiple Sclerosis in 8 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foley, P | 1 |
| Parker, RA | 4 |
| de Angelis, F | 3 |
| Connick, P | 3 |
| Chandran, S | 3 |
| Young, C | 1 |
| Weir, CJ | 4 |
| Chataway, J | 4 |
| Plantone, D | 3 |
| Doshi, A | 3 |
| John, N | 2 |
| Stutters, J | 3 |
| MacManus, D | 3 |
| Prados Carrasco, F | 2 |
| Barkhof, F | 3 |
| Ourselin, S | 2 |
| Braisher, M | 2 |
| Ross, M | 2 |
| Cranswick, G | 2 |
| Pavitt, SH | 2 |
| Giovannoni, G | 2 |
| Gandini Wheeler-Kingshott, CA | 2 |
| Hawkins, C | 2 |
| Sharrack, B | 2 |
| Bastow, R | 2 |
| Stallard, N | 2 |
| Solanky, BS | 1 |
| John, NA | 1 |
| DeAngelis, F | 1 |
| Prados, F | 1 |
| Schneider, T | 1 |
| Monteverdi, A | 1 |
| Marshall, I | 1 |
| Gandini Wheeler-Kingshott, CAM | 1 |
| Sulehria, T | 1 |
| Corbett, AM | 1 |
| Sharma, N | 1 |
| Nagarajan, D | 1 |
| Abushamma, A | 1 |
| Gagle, S | 1 |
| Johnson, A | 1 |
| Cambron, M | 2 |
| Mostert, J | 2 |
| D'Hooghe, M | 2 |
| Nagels, G | 2 |
| Willekens, B | 2 |
| Debruyne, J | 2 |
| Algoed, L | 2 |
| Verhagen, W | 2 |
| Hupperts, R | 2 |
| Heersema, D | 2 |
| De Keyser, J | 3 |
| Haentjens, P | 1 |
| Van Hecke, W | 1 |
| De Klippel, N | 1 |
| Fosselle, E | 1 |
| Laureys, G | 1 |
| Merckx, H | 1 |
| Van Wijmeersch, B | 1 |
| Vanopdenbosch, L | 1 |
| Hengstman, G | 1 |
| Michiels, V | 1 |
| Van Merhaegen-Wieleman, A | 1 |
| Mostert, JP | 1 |
| Admiraal-Behloul, F | 1 |
| Hoogduin, JM | 1 |
| Luyendijk, J | 1 |
| Heersema, DJ | 1 |
| van Buchem, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.[NCT01910259] | Phase 2 | 445 participants (Actual) | Interventional | 2014-12-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for fluoxetine and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, C | 2022 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Flu | 2020 |
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Topics: Adult; Amiloride; Aspartic Acid; Biomarkers; Child, Preschool; Cohort Studies; Cross-Sectional Studi | 2020 |
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple scl
Topics: Adult; Amiloride; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Multiple Scler | 2018 |
Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Topics: Adult; Aged; Belgium; Brain; Clinical Protocols; Cognition; Disability Evaluation; Disease Progressi | 2014 |
Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study.
Topics: Adult; Brain; Double-Blind Method; Female; Fluoxetine; Humans; Inflammation; Magnetic Resonance Imag | 2008 |
2 other studies available for fluoxetine and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Increasing Progenitor Cell Proliferation in the Sub-Ventricular Zone: A Therapeutic Treatment for Progressive Multiple Sclerosis?
Topics: Animals; Ascorbic Acid; Cell Proliferation; Drug Therapy, Combination; Female; Fluoxetine; Lateral V | 2020 |
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Topics: Clinical Trials, Phase II as Topic; Fluoxetine; Humans; Multiple Sclerosis, Chronic Progressive; Sel | 2019 |